1670-49-1

Basic information

• Product Name: 3-Methoxy-1,3,5(10),9(11)-estratetren-17-one
• Synonyms: 3-Methoxy-1,3,5(10),9(11)-estratetren-17-one
• CAS NO: 1670-49-1
• Molecular Formula: C₁₉H₂₂O₂
• Molecular Weight: 282.38
• Mol File: 1670-49-1.mol
• Article Data: 26

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Methoxy-1,3,5(10),9(11)-estratetren-17-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methoxy-1,3,5(10),9(11)-estratetren-17-one(1670-49-1)
• EPA Substance Registry System: 3-Methoxy-1,3,5(10),9(11)-estratetren-17-one(1670-49-1)

Safety Data

• Hazardous Substances Data: 1670-49-1(Hazardous Substances Data)

Usage

Classification

Synthetic compound belonging to the class of anabolic-androgenic steroids (AAS)

Derivation

Derived from nandrolone, a naturally occurring hormone in the human body

Main Properties

1. Anabolic Effects: Known for its strong anabolic effects
2. Popularity: Popular among bodybuilders and athletes for enhancing muscle growth and physical performance
3. Legal Status: Banned in competitive sports due to its potential for abuse and adverse health effects

Form of Availability

Sold as a dietary supplement or performance-enhancing drug

Risk Awareness

Important to be aware of potential risks and legal implications before use

Upstream product

• 1624-62-0 estrone 3-methyl ether 
• 1089-80-1 3-hydroxy-estra-1,3,5⁽¹⁰⁾,9⁽¹¹⁾-tetraen-17-one 
• 77-78-1 dimethyl sulfate 
• 53-16-7 Estrone 
• 2911-86-6 (+/-)-3-methoxyestra-1,3,5⁽¹⁰⁾,8-tetraen-17-one 
• 79066-30-1 1-formyl-6-methoxy-3,4-dihydronaphthalene 
• 1456-50-4 3-methoxyestra-1,3,5⁽¹⁰⁾,8,14-pentaen-17-one 
• 2811-50-9 7-methoxy-4-vinyl-1,2-dihydronaphthalene 
• 1120-73-6 2-methyl-2-cyclopenten-1-one 
• 966-46-1 (+/-)-9,11-dehydro-8-epiestrone 
• 899-79-6 2-[2-(3,4-dihydro-6-methoxy-1(2H)-naphthalenylidene)ethyl]-2-methyl-1,3-cyclopentanedione 
• 3125-36-8 6-methoxy-1-vinyl-1,2,3,4-tetrahydronaphthalen-1-ol 
• 1078-19-9 6-methoxy-3,4-dihydro-1(2H)-naphthalenone 
• 28336-29-0 17,17-ethylenedioxy-3-methoxyoestra-1,3,5⁽¹⁰⁾-triene 

Downstream Products

• 1624-62-0 estrone 3-methyl ether 
• 966-46-1 rac-3-Methoxy-1,3,5⁽¹⁰⁾,9⁽¹¹⁾-oestratetraen-17-on 
• 2911-86-6 (+/-)-3-methoxyestra-1,3,5⁽¹⁰⁾,8-tetraen-17-one 
• 53-16-7 Estrone 
• 28336-29-0 17,17-ethylenedioxy-3-methoxyoestra-1,3,5⁽¹⁰⁾-triene 
• 3907-67-3 3-O-methylequilinine 
• 1091-94-7 (+/-)-oestrone methyl ester 
• 966-47-2 3-methoxy-estra-1,3,5⁽¹⁰⁾,8⁽⁹⁾,14⁽¹⁵⁾-pentaene-17-one 

Relevant articles and documents

Regio- and stereoselective azidation of 19 norsteroids

The proton at C-9 of 3-methoxyestra-1,3,5(10)-trienes 1-4 was replaced by an azido group regio- and stereospecifically in one step by reaction with hydrazoic acid in chloroform in the presence of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ).

The structure and function of oestrogens. IV. Synthesis of 17α-ethynyloestradiol specifically polydeuterated in ring C

-

A [4+1] cyclopentannulation route to ring A aromatic, C(1)-C(11) methano-bridged steroids

In a novel, one-pot [4+1] cyclopentannulation procedure, the steroidal olefin 2 and CH2O are converted into the corresponding C(1)-C(11) methano-bridged derivative 3 by two sequential Lewis acid-promoted electrophilic substitutions. Birch reduction of the olefin 3, followed by removal of the protecting groups, affords 1,11α-methano-9β-estra-1,3,5(10)-triene-3,17β-diol (6).

Zn-Mediated Hydrodeoxygenation of Tertiary Alkyl Oxalates

Herein we describe a general, mild, and scalable method for hydrodeoxygenation of readily accessible tertiary alkyl oxalates by Zn/silane under Ni-catalyzed conditions. The reduction method is suitable for an array of structural motifs derived from tertiary alcohols that bear diverse functional groups, including the synthesis of a key intermediate en route to estrone.

CORTISTATIN ANALOGUES AND SYNTHESES AND USES THEREOF

Provided herein are compounds of Formula (A), (B), (C), (D) and (E), pharmaceutically acceptable salts, quaternary amine salts, and N-oxides thereof, and pharmaceutical compositions thereof. Compounds of Formula (A), (B), (C), (D), and (E) are contemplated useful as therapeutics for treating a wide variety of conditions, e.g., including but not limited to, conditions associated with angiogenesis and with CDK8 and/or CDK19 kinase activity. Further provided are methods of inhibiting CDK8 and/or CDK19 kinase activity, methods of modulating the β-catenin pathway, methods of modulating STAT1 activity, methods of modulating the TGFβ/BMP pathway, methods of modulating HIF-1 -alpha activity in a cell, and methods of increasing BIM expression to induce apoptosis, using a compound of Formula (A), (B), (C), (D), or (E). Further provided are CDK8 and CDK19 point mutants and methods of use thereof.